Bayer Aktiengesellschaft (FRA:BAYA)
| Market Cap | 54.82B +103.9% |
| Revenue (ttm) | 45.77B -0.2% |
| Net Income | -1.45B |
| EPS | -0.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.13 |
| Dividend | 0.02 (0.15%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | n/a |
| Open | 13.70 |
| Previous Close | 13.80 |
| Day's Range | 13.70 - 13.70 |
| 52-Week Range | 6.50 - 14.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Judge approves $7.25bn Bayer settlement for Roundup cancer claims
A Missouri judge on Friday approved a $7.25bn (£5.5bn) settlement stemming from lawsuits alleging that Bayer's weedkiller Roundup causes cancer. Judge Timothy Boyer said the settlement was "fair, rea...
US judge approves $7.25bn Roundup cancer settlement
WASHINGTON - A US judge on Friday approved Bayer's $7.25 billion settlement of lawsuits over claims its Roundup weedkiller caused blood cancer, in one of the largest class-action payouts in US history...
Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer
German company faced 65,000 claims from people who said they developed cancer after using weedkiller A Missouri judge on Friday approved Bayer ’s $7.25bn settlement of lawsuits alleging that its weed...
Tandem Global Welcomes Chitkala Kalidas of Bayer to Its Board of Directors
Kalidas joins an accomplished Board bringing together senior executives from some of the world's leading companies across industries. BETHESDA, MD / ACCESS Newswire / November 20, 2026 / Tandem Glo...
Missouri judge approves Bayer's $7.25 billion Roundup settlement
A Missouri judge on Friday approved Bayer's $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could ultimately resolve litigation that has weighe...
Bayer $7.25B Roundup settlement approved by judge, Bloomberg says
St. Louis Circuit Judge Timothy Boyer approved a Bayer (BAYRY) proposal to pay as much as $7.25B to resolve tens of thousands of U.S. lawsuits by people who blame the…
Bayer’s Sunharbo is now available to order in the U.S.
Bayer (BAYRY) announced that Sunharbo, 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for…
Bayer's SUNHARBO® (asundexian) Now Available in the United States
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immedia...
Evogene (EVGN) Q3 2026 Earnings Call Transcript
Bayer agreement expiry and warrant costs weighed on results as new AI-designed candidates advanced.
A New Pill Could Reduce the Risk of Having a Second Stroke
The daily pill by Bayer represents a new way to lower the risk of recurrent strokes.
Reuters NEXT returns to New York in December with Portugal Foreign Minister, Kraft Heinz CEO, Bayer CEO and more
Reuters today announced the speaker lineup for its annual Reuters NEXT leadership summit, taking place in New York on December 1–2, 2026. The two-day event will bring together global CEOs, policy make...
German chemicals lobby lifts 2026 sales forecast, but warns recovery remains elusive
German chemicals lobby VCI on Thursday raised its 2026 industry sales forecast on the back of higher prices, but warned the temporary boost from supply disruptions tied to the Iran war had faded.
Seven organisations pledge $65m to reduce maternal, newborn deaths in Nigeria
The seven organisations are DP World, Bayer, UNICEF, dsm-firmenich, Nestlé Nutrition Institute, Roche and Ferring Pharmaceuticals. The post Seven organisations pledge $65m to reduce maternal, newborn ...
Bayer’s Sunharbo approved by FDA to reduce risk of stroke
The company states: “Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved SUNHARBO(R) (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.
Bayer Secures FDA Nod For SUNHARBO In Secondary Stroke Prevention
(RTTNews) - Bayer AG (BAYN.DE, BYR.L) announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO (asundexian) in combination with antiplatelet therapy to reduce the risk of strok...
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Rece...
A new type of blood thinner approved on Monday is the first shown in testing to prevent repeat strokes without significantly increasing a person's bleeding risk
Bayer's drug, when added to blood thinners, helped reduce the risk of second strokes without increased bleeding risks.
US FDA approves Bayer's blood thinner to prevent repeat strokes
The US Food and Drug Administration on Monday approved a new type of blood thinner developed by Bayer for the prevention of strokes in patients who have already had one or have had a "mini-stroke."
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
We aim to use AI to cut down drug innovation time by 30%: Bayer Pharmaceuticals
Bayer Pharmaceuticals' COO Sebastien Guth discusses how important the use of AI is to the various aspects of the business. He also says the company is now getting regulatory approvals in China and, ho...
Luke Bryan's Farm Tour awards 97 college scholarships and helps provide 11 million meals since 2009
Since its inception in 2009, Luke Bryan's Farm Tour has championed educational opportunities by awarding 97 scholarships and supplying over 11 million meals for needy families. Partnering with Bayer’s...
BAYRY vs. JNJ: Which Stock Is the Better Value Option?
BAYRY vs. JNJ: Which Stock Is the Better Value Option?
Bayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity
PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce...
Bayer seeks bigger role in fast-growing Latin American biologicals market
Bayer said on Wednesday it will launch 17 new biological products in Latin America by 2030, including biopesticides and crop performance enhancers, as it targets a market growing faster than the gl...